Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Cauc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacogenomics J
Main Authors: Saladores, P, Mürdter, T, Eccles, D, Chowbay, B, Zgheib, N K, Winter, S, Ganchev, B, Eccles, B, Gerty, S, Tfayli, A, Lim, J S L, Yap, Y S, Ng, R C H, Wong, N S, Dent, R, Habbal, M Z, Schaeffeler, E, Eichelbaum, M, Schroth, W, Schwab, M, Brauch, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4308646/
https://ncbi.nlm.nih.gov/pubmed/25091503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2014.34
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados